04 Nov Genome-wide characterization of CTCF binding sites and related gene pathways in the pathogenesis of Myelodysplastic Syndromes Posted at 14:46h in Submission by Anna Scotti (staff) 0 Comments 0 Likes Claudia Brunetti Read More
04 Nov Immunophenotypic analysis of hematopoiesis in patients suffering from shwachman –bodian-diamond syndrome Posted at 14:28h in Submission by Anna Scotti (staff) 0 Comments 0 Likes Angela Mercuri Read More
04 Nov Prospective evaluation of a putative pro-atherothrombotic status and genetic predisposition in the pathogenesis of peripheral arterial occlusive disease and other atherothrombotic episodes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Posted at 14:23h in Submission by Anna Scotti (staff) 0 Comments 0 Likes Lara Aprile Read More
04 Nov Clinical impact of low burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients: the type of mutation matters Posted at 14:16h in Submission by Anna Scotti (staff) 0 Comments 0 Likes Caterina de Benedittis Read More
04 Nov Leukemic Microenvironment and Inflammation. The Tissue Inhibitor of MetalloProteinases-1 (TIMP-1) impacts the in vitro behaviour of leukemic cells through CD63/PI3K/AKT/P21 axis Posted at 13:58h in Submission by Anna Scotti (staff) 0 Comments 0 Likes Dorian Forte Read More
04 Nov Notch signaling drives bone marrow stromal cell-mediated chemoresistance in acute myeloid leukemia Posted at 13:56h in Submission by Anna Scotti (staff) 0 Comments 0 Likes Giulio Bassi Read More
04 Nov Unraveling the Efficacy and Safety Profiles of Anti-CD123 Chimeric Antigen Receptors (CARs) in an in vitro Model of Acute Myeloid Leukemia Immunotherapy By Investigating CAR Binding Affinity and Density Variables Posted at 13:53h in Submission by Anna Scotti (staff) 0 Comments 0 Likes Silvia Arcangeli Read More
04 Nov Neurological symptoms in essential thrombocythemia: impact of JAK2V617F mutation and response to therapy Posted at 13:52h in Submission by Anna Scotti (staff) 0 Comments 0 Likes Elena Maria Elli Read More
04 Nov JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo Posted at 13:50h in Submission by Anna Scotti (staff) 0 Comments 0 Likes Paolo Gallipoli Read More
04 Nov Toll-like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation Posted at 13:43h in Submission by Anna Scotti (staff) 0 Comments 0 Likes Eleonora Fonte Read More
